Century Therapeutics, Inc. (IPSC) stock
Close on Nov 11, 2026Market cap $315.07MP/E –Yield –
Century Therapeutics, Inc. grew revenue 1556.8% to $109.16M over fiscal 2025. Free cash flow was -$85.08M. At the latest close the market valued the company at $315.07M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $315.07M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.36
- Dividend yield
- –
- Free cash flow yield
- -27.96%
Fundamentals
- Revenue
- $109.16M
- Net income
- -$98.82M
- EPS, diluted
- -$0.61
- Free cash flow
- -$85.08M
- Book value per share
- $1.02
- Diluted shares
- 206M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $1.68
- Open
- $1.74
- Day's range
- $1.64 – $1.75
- Volume
- 327,763
- Average volume (20 days)
- 1,004,740
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.37
- 52-week range
- $0.43 – $3.04
- RSI (14 days)
- 56.7
- Volatility (1 year)
- 102.5%
- Relative volume
- 0.43×
- WACC
- 11.7%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IPSC | S&P 500 | Difference | IPSC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +18.4% | -2.4% | +20.8 pts | ||
| 3 months | -15.5% | -1.2% | −14.4 pts | ||
| Year to date | +74.9% | +12.3% | +62.6 pts | ||
| 1 year | +208.9% | +12.4% | +196.4 pts | ||
| 3 years | +34.9% | +78.8% | −43.9 pts | +10.5% | +21.4% |
| 5 years | -91.7% | +75.2% | −166.9 pts | -39.2% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Century Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Results
- News
About Century Therapeutics
Biological Products, (No Diagnostic Substances)
Century Therapeutics is a biotechnology company that develops allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells. The company focuses on treatments for autoimmune diseases, type 1 diabetes, and cancers. Its primary pipeline candidates include CNTY-813, an engineered beta islet cell replacement therapy for type 1 diabetes; CNTY-308, a chimeric antigen receptor T-cell therapy targeting B-cell-mediated disorders; and CNTY-101, a natural killer cell therapy evaluated for autoimmune indications. It also designs additional programs for solid tumors and blood cancers. The company's therapies target patient populations living with serious metabolic, autoimmune, and oncologic illnesses.
Company profile, executives and historyCentury Therapeutics stock: common questions
What is Century Therapeutics's stock price?
IPSC closed at $1.74 on Nov 11, 2026, up 3.57% on the day. Over the past 52 weeks it traded between $0.43 and $3.04.
What is Century Therapeutics's market cap?
Century Therapeutics was worth $315.07M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IPSC's P/E ratio?
Century Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.61), so it has no meaningful P/E ratio.
How much revenue does Century Therapeutics make?
Century Therapeutics reported revenue of $109.16M for fiscal 2025, up 1556.8% from a year earlier.
Does Century Therapeutics pay a dividend?
No. Century Therapeutics has not paid a cash dividend over the last twelve months.
When does Century Therapeutics report earnings next?
Century Therapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IPSC stock performed over the past year?
Including dividends, IPSC returned +208.9% over the past year, against +12.4% for the S&P 500.
How many IPSC shares are sold short?
32M shares were sold short at the latest FINRA report, 18.38% of the float, or 31.0 days of average trading volume.
Who are Century Therapeutics's competitors?
Companies most similar to Century Therapeutics by business, industry and size include AUTL, KYMR, MESO, ADAPY, FDMT.
See a number that looks wrong?